Photodynamic Therapy for Basal Cell Carcinoma: The Clinical Context for Future Research Priorities

Collier, N.J.; Rhodes, Lesley E.

doi:10.3390/molecules25225398

Cited by 35 publications

(23 citation statements)

References 177 publications

(271 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Collier and Rhodes ( 74 ) provided an outline of knowledge based on an analysis of randomized controlled trials of topical PDT in BCC, introduced the mechanism of action of topical PDT, described the use 5-ALA/MAL as prodrugs, and discussed the development of strategies for enhancing penetration and optimizing PpIX accumulation (e.g., epigallocatechin-3-gallate, iron chelators). The correlation between BCC subtypes and the effect of PDT (superficial low-risk BCC displayed higher complete response rates to topical PDT than other subtypes of BCC) was revealed, and a comparison of topical PDT with other topical methods (e.g., surgical excision, cryosurgery, topical 5-FU, imiquimod) was reported.…”

Section: Application Of Nano-pdt In Skin Cancermentioning

confidence: 99%

Advances in Photodynamic Therapy Based on Nanotechnology and Its Application in Skin Cancer

et al. 2022

View full text Add to dashboard Cite

Comprehensive cancer treatments have been widely studied. Traditional treatment methods (e.g., radiotherapy, chemotherapy), despite ablating tumors, inevitably damage normal cells and cause serious complications. Photodynamic therapy (PDT), with its low rate of trauma, accurate targeting, synergism, repeatability, has displayed great advantages in the treatment of tumors. In recent years, nanotech-based PDT has provided a new modality for cancer treatment. Direct modification of PSs by nanotechnology or the delivery of PSs by nanocarriers can improve their targeting, specificity, and PDT efficacy for tumors. In this review, we strive to provide the reader with a comprehensive overview, on various aspects of the types, characteristics, and research progress of photosensitizers and nanomaterials used in PDT. And the application progress and relative limitations of nanotech-PDT in non-melanoma skin cancer and melanoma are also summarized.

show abstract

Section: Application Of Nano-pdt In Skin Cancermentioning

confidence: 99%

Advances in Photodynamic Therapy Based on Nanotechnology and Its Application in Skin Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Another evidence supporting a BCC-induced defective immune local response is the efficacy of therapies with a well know immunomediated mechanism, like both imiquimod and photodynamic therapy, in the treatment of BCC ( 34 , 35 ).…”

Section: Immunological Findings In Bccmentioning

confidence: 99%

Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response

et al. 2022

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common form of skin cancer, affecting more often elderly patients, but sometimes even younger ones, particularly if immunocompromised or genetically predisposed. Specifically, the Gorlin-Goltz syndrome, an autosomal dominant genodermatosis, also known as nevoid basal cell carcinoma syndrome, characterizes for multiple early onset BCCs. It is caused by a germline mutation in PTCH1, a tumor suppressor gene whose product is the key component of Hedgehog (Hh) signaling pathway, which also appears somatically mutated in more than 85% of sporadic BCCs. Hh pathway inhibitors vismodegib and sonidegib are currently indicated for BCC, in adults with advanced or recurred tumor following surgery or radiation therapy. The principal mechanism of action of these drugs is the inhibition of Smoothened (SMO), a transmembrane protein involved in Hh signal transduction, that plays a role in both cellular differentiation and cancer development. Some studies have reported effects of Hh pathway inhibitors at different levels of the immune response, from cytotoxic T cells to a modified local cytokines pattern. Given the specific relation between immune system and BCC development in some conditions, we will review BCC with focus on immune system changes mediated by Hh signaling pathway and induced by the inhibitors vismodegib and sonidegib in the treatment of BCC. Thus, we will give an overview of their effects on the local immune response, as well as a brief note on the supposed function of Hh pathway inhibition on the systemic one.

show abstract

“…[28] A photosensitizing pro-drug such as 5-aminolevulinic acid or methyl aminolevulinate is applied on the lesion which is then activated by light after an incubation period of 1 to a few hours. [29,30] e recommended wavelength for management of BCC is centered around 630 nm (red light). [31] In general, a single treatment cycle is enough, but non-responding lesions are given another course of PDT at 1 week.…”

Section: Imiquimodmentioning

confidence: 99%

Treatment of basal cell carcinoma: An overview

Bali

Deif

Rajeev

2022

JSSTD

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common cutaneous cancer worldwide, but accounts for only 2–4% of skin cancers in Asian population. Tumor characteristics such as size, location, pathology, and risk of recurrence, as well as treatment tolerability, cost, and patient preference influence the selection of treatment. The goal of treatment is complete tumor removal in superficial/locally invasive BCCs and prolongation of survival in the rare setting of metastatic BCC. Various treatment options available include conventional surgical excision, Mohs micrographic surgery, cryosurgery, electrodesiccation and curettage, topical application of imiquimod or 5-fluorouracil, and photodynamic, and radiotherapy. Surgical excision and Mohs surgery are preferred because of low recurrence rate and the possibility to evaluate the clearance through histology. In the treatment of metastatic or locally advanced lesions, hedgehog pathway inhibitors and the recently approved drug cemiplimab can be beneficial. Sun protection and regular skin self-checks are recommended for all patients with BCC. This literature review gives an overview of the treatment of BCC.

show abstract

Photodynamic Therapy for Basal Cell Carcinoma: The Clinical Context for Future Research Priorities

Cited by 35 publications

References 177 publications

Advances in Photodynamic Therapy Based on Nanotechnology and Its Application in Skin Cancer

Advances in Photodynamic Therapy Based on Nanotechnology and Its Application in Skin Cancer

Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response

Treatment of basal cell carcinoma: An overview

Contact Info

Product

Resources

About